Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 403-418

  Taggart, D ^a   Dubois, S ^a   Matthay, K K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 Iodobensylguanidine; Neuroblastoma; Radiolabelling

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; HISTONE DEACETYLASE INHIBITOR; IODINE 123; IODINE 131; IRINOTECAN; MELPHALAN; NORADRENALIN TRANSPORTER; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; RADIOSENSITIZING AGENT; TOPOTECAN; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADRENAL DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG UPTAKE; ENDOCRINE DISEASE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; HYPERTHYROIDISM; HYPOGONADISM; HYPOTENSION; HYPOTHYROIDISM; INFECTION; INFERTILITY; ISOTOPE LABELING; LIVER DISEASE; LIVER TOXICITY; MONITORING; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; PAIN; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SALIVARY GLAND PAIN; SECOND CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

3-IODOBENZYLGUANIDINE; HUMANS; NEUROBLASTOMA; RADIATION-SENSITIZING AGENTS; RADIOMETRY; RECURRENCE; STAINING AND LABELING;

EID: 60549088714     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer 1992;52:538-43.
2. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
4. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
5. 131I-MIBG) double infusion with autologous stem cell rescue for neuroblastoma: a New Approaches to Neuroblastoma (NANT) Phase 1 study. J Clin Oncol. In press 2008.
6. Wieland DM, Mangner TJ, Inbasekaran MN, Brown LE, Wu JL. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984;27:149-55.
7. 131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
8. Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997;38:1352-7.
9. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
10. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
11. Shimada H, Arnbros IM, Delmer LP, Hata J, Joshi VV, Roald B et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
12. Attiveh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D et al.; Children's Oncology Group. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53.
13. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61.
14. Paltiel HJ, Gelfand MJ, Elgazzar AH, Washburn LC, Harris RE, Masters PR et al. Neural crest tumors: I-123 MIBG imaging in children. Radiology 1994;190:117-21.
15. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129-34.
16. 123I-metaiodobenzlyguanidine scans in neuroblastoma. A report for the International Neuroblastoma Risk Group (INRG) Task Force. 2008.
17. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-88.
18. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998;77:2061-8.
19. Monclair T, Brodeur G, Ambros PF et al. The International Neuroblastoma Rick Group (INRG) Staging System. In press 2008.
20. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302.
21. Matthay KK, Brisse H, Couanet D, Couturier J, Bénard J, Mosseri V et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 2003;98:155-65.
22. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9.
23. Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering Cancer Center experience and a literature review. Cancer 2001;91:1510-9.
24. Hero B, Hunneman DH, Gahr M, Berthold F. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 2001;36:220-3.
25. Brans B, Laureys G, Schelfhout V, Wiele CV, Potter CR, Dhooge C et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to turnout differentiation in vivo. Eur J Nucl Med 1998;25:144-9.
26. 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115-24.
27. Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082-6.
28. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405.
29. Shulkin BL, Hutchinson RL Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
30. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996;37:16-21.
31. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-90.
32. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004;22:3909-15.
33. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-91.
34. Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999;21:13-8.
35. Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 2003;39:1899-903.
36. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008; 44:1552-8.
37. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16:953-65.
38. 123I-MIBG whole body scan scoring method - application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A:256-61.
39. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 2000;34:237-41.
40. Suc A, Lumbroso J, Rubie H, Hattchouel JM, Boneu A, Rodary C et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77:805-11.
41. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74.
42. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008;35:S1:35-S31:48.
43. Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, Schlumberger M et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 1995;22:1180-3.
44. Hickeson MP, Charron M, Maris JM, Brophy P, Kang TI, Zhuang H et al. Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004;42:268-74.
45. Parisi MT, Matthay KK, Huberty JP, Hattner RS. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology 1992;184:463-7.
46. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000;18:18-26.
47. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998;16:1256-64.
48. Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;52:44-50.
49. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005;23:6474-80.
50. Cohn SL, Pearson AD, London WB et al. The international neuroblastoma rick group (INRG) classification system. J Clin Oncol. 2008; in press.
51. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348-57.
52. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6:649-58.
53. 131I-metaiodobenzylguanidine. Eur J Nucl Med 1988;14:337-40.
54. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-36.
55. Wafelman AR, Nortier YL, Rosing H, Maessen HJ, Taal BG, Hoefnagel CA et al. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun 1995;16:767-72.
56. 131I]iodobenzylguanidine in patients. Cancer Res 1987; 47:6147-9.
57. 131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol 1989;25:143-8.
58. 131I-metaiodobenzylguanidine. Cancer 2003;97:1332-8.
59. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-60.
60. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-60.
61. 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer 2008;50:1271-3.
62. Van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabelled children with neuroblastoma. Cancer 2003;98:389-96.
63. Picco P, Garaventa A, Claudiani F, Gattorno M, De Bernardi B, Borrone C. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995;76:1662-4.
64. 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 2003;25:543-7.
65. 131I-MIBG: dosimetric problems and perspectives. Med Pediatr Oncol 1987;15:188-91.
66. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308-16.
67. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10:1889-96.
68. 131I-MIBG therapy for neuroblastoma in children. Br J Radiol 1995;68:481-90.
69. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713-21.
70. 131I-mIBG therapy of neuroblastoma. Phys Med Biol 1996;41:1933-40.
71. Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18:81-7.
72. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991;35:244-7.
73. 131I]metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy. J Nucl Biol Med 1991;35:232-6.
74. 131I]metaiodobenzylguanidine: long-term results in 25 patients. J Nucl Biol Med 1991;35:216-9.
75. 131I]metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med 1991;35:207-15.
76. 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003;25:769-73.
77. 131I]metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med 1991;35:224-7.
78. 131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 1999; 81:1378-84.
79. 131I]metaiodobenzylguanidine treatment of refractory advanced neruroblastoma. J Nucl Biol Med 1991;35:237-40.
80. Hutchinson RJ, Sisson JC, Shapiro B, Miser JS, Normole D, Shulkin BL et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 1992;15:226-32.
81. 131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991;35:220-3.
82. 131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 1991;35:202-6.
83. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005;44:232-9.
84. 131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 1991; 35:228-31.
85. 131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995;31A:252-6.
86. Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V et al. Treatment of advanced neutoblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001;84:460-4.
87. Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S, Villavecchia GP et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001;27:571-4.
88. 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998;34:1398-402.
89. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-9.
90. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24:500-6.
91. www.nant.org.
92. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551-6.
93. Klingebiel T, Berthold F, Treuner J, Schwabe D, Fischer M, Feine U et al. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol 1991;19:84-8.
94. 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006;45:145-51; quiz N39-40.
95. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-9.
96. 131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 2005;11:7929-37.
97. Voûte PA, van der Kleij Aj, De Kraker J, Hoefnagel CA, Tiel-van Buul MM, Van Gennip H. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 1995;31A:596-600.
98. Mastrangelo R, Tornesello A, Lasorella A, Iavarone A, Mastrangelo S, Riccardi R et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 1997;31:153-8.
99. 131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995;31A:606-11.
100. De los Santos M, Martinez-Iglesias O, Aranda A. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells. Endocr Relat Cancer 2007;14:1021-8.
101. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120:1787-94.
102. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007;99:1107-19.
103. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25: 4051-6.
104. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005;62:223-9.
105. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 2006;1:25.
106. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5:1967-74.
107. 125I]meta-iodobenzylguanidine. Int J Radiat Oncol Biol Phys 1998;41:425-32.
108. 125I]metaiodobenzylguanidine. J Nucl Biol Med 1991;35:255-9.